Načítá se...
Cervical cancer – State of the science: From angiogenesis blockade to checkpoint inhibition
Vascular endothelial growth factor (VEGF) has emerged as a therapeutic target in several malignancies, including cervical cancer. Chemotherapy doublets combined with the fully humanized monoclonal antibody, bevacizumab, now constitute first-line therapy for women struggling with recurrent/metastatic...
Uloženo v:
| Vydáno v: | Gynecol Oncol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6720107/ https://ncbi.nlm.nih.gov/pubmed/29666026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2018.01.009 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|